CompletedNCT00421954
Ziprasidone for psychosis in adolescents
About this title
Read the official source — NCT00421954Medication studyAges 13–17United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 13 years to 17 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 8
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT00421954
- Official title
Show the full official title
Open-label Feasibility Study for the Treatment of Psychotic Adolescents With Ziprasidone in the Inpatient and Day Hospital Settings
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Ziprasidone.
Who was this study for?
Listed age limits: 13 years to 17 years.
